Table 1 Descriptive characteristics of the patients

Total number

210

Females/males

149 (71 %)/61 (29 %)

Age (years)

Mean 14.4 (SD 3.40) Median 15.00 (Range 7–21)

Height (m)

Mean 1.60 (SD 0.15) Median 1.62 (Range 1.14–1.87)

Weight (kg)

Mean 52.8 (SD 15.9) Median 53.8 (Range 18.5–97.0)

BMI SDS ^a

Mean 0.4 (SD 1.17) Median 0.50 (Range −3.2–3.6)

Waist-to-height ratio (163 patients)

Mean 0.44 (SD 0.04) Median 0.43 (Range 0.35–0.62)

Tanner Stadium

121 (57.6 %) in Tanner Stage 5

 - Systemic

6 (2.9 %)

 - Persisting Oligoarticular

65 (31 %)

 - Polyarticular, RF negative

53 (25 %)

 - Polyarticular, RF positive

8 (3.8 %)

 - Psoriasis associated

21 (10.0 %)

 - Enthesitis associated

56 (26.7 %)

 - Undifferentiated

1 (0.5 %)

 - Anti-Nuclear Antibodies (ANA) positive

32 (15.2 %)

 - HLA-B27 positive

40 (19 %)

 - Methotrexate

40 (19 %)

 - Biologics +/− Methotrexate:

142 (68 %)

either TNF-α inhibitors

130

or IL-6 receptor inhibitor

4

or T-cell co-stim inhibitor CTLA-4-Ig

8

 - Solely by intra-articular injections

13 (6.2 %)

 - None

10 (4.8 %)

 - No information

4 (1.9 %)

Disease duration ^b in years

Mean 6.1 (SD 3,7) Median 5.2 (Range 0.5–17.3)

Complete remission off medication

4 (1.9 %)